Eli Lilly (NYSE:LLY) Hits a Record High on Weight-Loss Drug Optimism: Buy or Too Late?

Eli Lilly (NYSE:LLY) hit a fresh all-time high on Tuesday, rising about 3% to near US$1,236 after JPMorgan lifted its price target on the stock to US$1,400. The drugmaker is now worth more than US$1.1 trillion, making it one of the largest healthcare companies on earth. The excitement is all about weight-loss drugs, but with the stock at a record, the real question for investors is whether there is still room to run or whether the easy gains are gone.

Why the Weight-Loss Boom Keeps Driving Eli Lilly Higher

To understand the enthusiasm, you need to know Lilly’s two blockbuster drugs: Mounjaro, for diabetes, and Zepbound, for weight loss. Both belong to a class of medicines known as GLP-1s, and demand for them has been staggering as obesity treatment goes mainstream. JPMorgan’s analyst believes this is still early, describing the obesity market as heavily underpenetrated, meaning most people who could use these drugs are not yet taking them.

There is more to come, too. In April 2026, Eli Lilly won FDA approval for orforglipron, sold as Foundayo, a weight-loss drug in pill form rather than as an injection. This is a big deal, because a pill could reach far more patients who dislike needles, and it is already on the market rather than a distant hope.

On top of that, a new Medicare programme started on 1 July that lets eligible patients get Lilly’s weight-loss drugs for a US$50 monthly copay, potentially opening the door to millions of new customers. In our view, this combination of a huge untapped market, a newly launched oral drug, and wider insurance access is exactly why analysts keep raising their targets.

The Catch: A Record Price and a Safety Question

Here is the reality check. After climbing to a record, Eli Lilly trades at about 44 times earnings. That is expensive, though not unreasonable for a company growing sales at more than 25% a year. Still, it means the market already expects years of strong growth, so the stock needs Lilly to keep delivering just to justify today’s price, the same high-expectations problem now hanging over expensive AI stocks. JPMorgan’s US$1,400 target implies only about 13% further upside, which tells you a lot of the good news is already baked in.

There is also a safety point investors should understand, without overreacting to it. When the FDA approved Foundayo, it attached routine post-approval studies covering possible liver, heart, and thyroid risks, a standard caution for a brand-new type of drug. Lilly’s own trials, covering more than 11,000 patients, showed a clean liver safety profile, and analysts have largely treated the occasional safety headline as noise.

The takeaway is that the fundamentals look solid, but the stock is highly sensitive to safety news, so any negative headline could still knock it around in the short term. Competition from rival Novo Nordisk, whose own weight-loss pill is on the market, is another pressure point.

The Investor’s Takeaway for Eli Lilly

Our take: Eli Lilly is a genuinely great business riding one of the biggest healthcare trends in a generation, but buying at an all-time high always demands caution. This is not a bargain; it is a premium price for a premium company.

For long-term investors who believe the weight-loss market will keep growing for years, Lilly remains a high-quality way to play that theme, and pullbacks may offer better entry points than chasing the record, much as they have for other momentum leaders trading at rich valuations.

More cautious investors might wait for the August earnings report, or for a pullback from these record levels, before buying. The growth story is real. Whether it is still a bargain at 44 times earnings is the harder question, and the answer depends on Eli Lilly continuing to execute almost flawlessly.